[go: up one dir, main page]

HUP0302339A2 - Mammalian receptor subunit proteins, related reagents and methods - Google Patents

Mammalian receptor subunit proteins, related reagents and methods

Info

Publication number
HUP0302339A2
HUP0302339A2 HU0302339A HUP0302339A HUP0302339A2 HU P0302339 A2 HUP0302339 A2 HU P0302339A2 HU 0302339 A HU0302339 A HU 0302339A HU P0302339 A HUP0302339 A HU P0302339A HU P0302339 A2 HUP0302339 A2 HU P0302339A2
Authority
HU
Hungary
Prior art keywords
subject
methods
dcrs5
immune system
receptor subunit
Prior art date
Application number
HU0302339A
Other languages
Hungarian (hu)
Inventor
Madaline Chirica
Robert A. Kastelein
Kevin W. Moore
Christi L. Parham
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22753958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302339(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0302339A2 publication Critical patent/HUP0302339A2/en
Publication of HUP0302339A3 publication Critical patent/HUP0302339A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

A találmány tárgyát képezik emlősszervezet fiziológiáját, beleértve azimmunrendszer funkcióját befolyásolni képes készítmények és eljárások.A találmány tárgyát képezik eljárások a fejlődés és/vagy azimmunrendszer szabályzására. A találmány tárgyát citokinreceptorokkalrokon szerkezetű, új receptorok, például főemlősből származó,citokinreceptorszerű molekuláris struktúrák képezik, melyek elnevezéseDNAX citokinreceptor-alegységek (DCRS), különösen egy alegység, aDCRS5-jelű, valamint biológiai aktivitásaik. A találmány tárgyátképezik magukat a polipeptideket kódoló nukleinsavak, éselőállításukra szolgáló eljárások és alkalmazásuk. Továbbá a találmánytárgyát képezi a p40/IL-B30-ligandum párosíthatósága a DCRS5- és IL-12Rb1-receptoralegységekkel, amely párosodás betekintést biztosítspecifikus agonistákat és antagonistákat alkalmazó indikációkba.Szintén a találmány tárgyát képezik ilyen anyagok diagnosztikai ésterápiás alkalmazásai. ÓThe subject of the invention is the physiology of a mammalian organism, including compositions and methods capable of influencing the function of the immune system. The subject of the invention is methods for regulating development and/or the immune system. The subject of the invention is new receptors with a structure related to cytokine receptors, for example cytokine receptor-like molecular structures from primates, which are called DNAX cytokine receptor subunits (DCRS), especially one subunit, DCRS5, and their biological activities. The subject of the invention is the nucleic acids encoding the polypeptides themselves, and the methods for their production and their use. Furthermore, the subject of the invention is the compatibility of the p40/IL-B30 ligand with the DCRS5 and IL-12Rb1 receptor subunits, which pairing provides insight into indications using specific agonists and antagonists. The invention also covers the diagnostic and therapeutic applications of such substances. HE

HU0302339A 2000-05-10 2001-05-10 Mammalian receptor subunit proteins, related reagents and methods HUP0302339A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20342600P 2000-05-10 2000-05-10
PCT/US2001/015057 WO2001085790A2 (en) 2000-05-10 2001-05-10 Mammalian cytokine receptor subunit proteins, related reagents and methods

Publications (2)

Publication Number Publication Date
HUP0302339A2 true HUP0302339A2 (en) 2003-10-28
HUP0302339A3 HUP0302339A3 (en) 2011-01-28

Family

ID=22753958

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302339A HUP0302339A3 (en) 2000-05-10 2001-05-10 Mammalian receptor subunit proteins, related reagents and methods

Country Status (25)

Country Link
US (7) US6756481B2 (en)
EP (3) EP1287130B2 (en)
JP (6) JP5073909B2 (en)
KR (1) KR100869621B1 (en)
CN (2) CN1575337A (en)
AT (1) ATE396264T1 (en)
AU (2) AU6135101A (en)
CA (1) CA2408571C (en)
CY (1) CY1108545T1 (en)
CZ (1) CZ304022B6 (en)
DE (1) DE60134136D1 (en)
DK (1) DK1287130T3 (en)
ES (1) ES2307618T3 (en)
HK (1) HK1049862B (en)
HU (1) HUP0302339A3 (en)
IL (2) IL152414A0 (en)
MX (1) MXPA02011081A (en)
NO (2) NO331408B1 (en)
NZ (1) NZ522146A (en)
PL (1) PL209128B1 (en)
PT (1) PT1287130E (en)
SI (1) SI1287130T1 (en)
SK (1) SK287984B6 (en)
WO (1) WO2001085790A2 (en)
ZA (1) ZA200208795B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
EP2135953B1 (en) 1999-06-02 2014-04-23 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, Nr. 10
WO2001023556A1 (en) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CN1575337A (en) * 2000-05-10 2005-02-02 先灵公司 Mammalian receptor proteins, related reagents and methods
CA2501786C (en) * 2002-10-30 2015-02-17 Genentech, Inc. Inhibition of il-17 production
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
BRPI0408247A (en) * 2003-03-10 2006-03-01 Schering Corp uses of il-23 antagonists and agonists and related reagents
US7247711B2 (en) 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
ATE533502T1 (en) * 2004-02-17 2011-12-15 Schering Corp METHOD FOR MODULATING IL-23 ACTIVITY; RELEVANT REAGENTS
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AR051444A1 (en) * 2004-09-24 2007-01-17 Centocor Inc PROTEINS DERIVED FROM IL-23P40 SPECIFIC IMMUNOGLOBULIN, COMPOSITIONS, EPITHOPES, METHODS AND USES
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
UA101301C2 (en) 2005-12-29 2013-03-25 Сентокор, Инк. Isolated il-23pl9 antibody and use thereof
KR20150091545A (en) 2006-06-08 2015-08-11 추가이 세이야쿠 가부시키가이샤 Preventive or remedy for inflammatory disease
TWI426918B (en) 2007-02-12 2014-02-21 Merck Sharp & Dohme Use of il-23 antagonists for treatment of infection
CN101675076B (en) 2007-02-28 2013-09-18 默沙东公司 Engineered anti-il-23r antibodies
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
US8431127B2 (en) * 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
NZ600584A (en) 2008-05-05 2014-05-30 Novimmune Sa Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
CA2759942A1 (en) * 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
EA030436B1 (en) 2010-11-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ANTI-IL-23p19 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF, USE THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THESE ANTIBODIES, METHOD FOR PRODUCING SAME, ISOLATED POLYNUCLEOTIDES, EXPRESSION VECTORS AND CELLS FOR PRODUCING ANTIBODIES
EA201401204A1 (en) 2012-05-03 2015-05-29 Бёрингер Ингельхайм Интернациональ Гмбх ANTIBODIES TO IL-23P19
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
ES2887549T3 (en) 2014-09-03 2021-12-23 Boehringer Ingelheim Int IL-23A and TNF-alpha targeting compound and uses thereof
IL310216A (en) 2018-03-05 2024-03-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (en) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Day and date setting device for clocks with calendar
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
JPH11273358A (en) 1998-03-26 1999-10-08 Kawasaki Steel Corp Semiconductor storage device
EP2258849A1 (en) * 1999-06-01 2010-12-08 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
ES2300276T5 (en) 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 of mammalian interleukin-12 and B30 interleukin. Your combinations Antibodies Uses in pharmaceutical compositions
WO2001023556A1 (en) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
JP2008099690A (en) 1999-09-27 2008-05-01 Chugai Pharmaceut Co Ltd Novel hemopoietin receptor protein, nr12
CN1575337A (en) * 2000-05-10 2005-02-02 先灵公司 Mammalian receptor proteins, related reagents and methods

Also Published As

Publication number Publication date
CY1108545T1 (en) 2014-04-09
DK1287130T3 (en) 2008-09-01
US7749718B2 (en) 2010-07-06
CZ20023698A3 (en) 2003-04-16
US7964703B2 (en) 2011-06-21
PL365177A1 (en) 2004-12-27
JP2008273961A (en) 2008-11-13
EP2275548A1 (en) 2011-01-19
JP2015110576A (en) 2015-06-18
KR100869621B1 (en) 2008-11-21
US6756481B2 (en) 2004-06-29
CA2408571A1 (en) 2001-11-15
PL209128B1 (en) 2011-07-29
JP2012187111A (en) 2012-10-04
US20090060865A1 (en) 2009-03-05
NO331408B1 (en) 2011-12-19
CN101654479A (en) 2010-02-24
AU2001261351B2 (en) 2007-03-01
SK287984B6 (en) 2012-08-06
US20030017617A1 (en) 2003-01-23
US8110378B2 (en) 2012-02-07
JP2015057396A (en) 2015-03-26
JP5073909B2 (en) 2012-11-14
CA2408571C (en) 2014-04-29
KR20020092472A (en) 2002-12-11
US20100261273A1 (en) 2010-10-14
ATE396264T1 (en) 2008-06-15
IL152414A (en) 2010-05-31
HK1049862A1 (en) 2003-05-30
SK15742002A3 (en) 2003-03-04
NZ522146A (en) 2004-10-29
PT1287130E (en) 2008-09-01
JP2012070740A (en) 2012-04-12
US20110243842A1 (en) 2011-10-06
MXPA02011081A (en) 2003-03-10
US7411041B2 (en) 2008-08-12
HUP0302339A3 (en) 2011-01-28
EP1287130B2 (en) 2017-07-26
ZA200208795B (en) 2004-02-09
EP1287130A2 (en) 2003-03-05
DE60134136D1 (en) 2008-07-03
US7510853B2 (en) 2009-03-31
WO2001085790A3 (en) 2002-07-18
CZ304022B6 (en) 2013-08-28
EP1918377A1 (en) 2008-05-07
HK1049862B (en) 2008-08-01
US20120121601A1 (en) 2012-05-17
SI1287130T1 (en) 2008-08-31
NO20025354L (en) 2003-01-10
US20050100918A1 (en) 2005-05-12
ES2307618T3 (en) 2008-12-01
EP1918377B1 (en) 2013-12-04
AU6135101A (en) 2001-11-20
NO20111147L (en) 2003-01-10
EP1287130B1 (en) 2008-05-21
NO20025354D0 (en) 2002-11-08
US20050100917A1 (en) 2005-05-12
WO2001085790A2 (en) 2001-11-15
CN1575337A (en) 2005-02-02
JP2003532408A (en) 2003-11-05
IL152414A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
HUP0302339A2 (en) Mammalian receptor subunit proteins, related reagents and methods
Kotenko et al. Other kinases can substitute for Jak2 in signal transduction by interferon-γ
Myers et al. Expression of functional RANK on mature rat and human osteoclasts
Weber-Nordt et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain
Nickel et al. The crystal structure of the BMP-2: BMPR-IA complex and the generation of BMP-2 antagonists
Bacon et al. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3
HUP0301102A2 (en) Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
Schroers et al. Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane
DE69230888D1 (en) SOMATOSTATIN RECEPTORS
Rose-John et al. “Family reunion”–A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines
Aparicio-Siegmund et al. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation
Dams-Kozlowska et al. A designer hyper interleukin 11 (H11) is a biologically active cytokine
ATE445011T1 (en) HEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES CODING THEREOF
ES2150898T3 (en) HUMAN RECEIVER FC (GAMMA) RIII.
Seldin et al. Mutational analysis of a critical signaling domain of the human interleukin 4 receptor.
Aparicio-Siegmund et al. Recombinant p35 from bacteria can form Interleukin (IL-) 12, but Not IL-35
ATE320489T1 (en) GFR-ALPHA3 AND ITS USES
ES2144399T3 (en) CLONING THE CHICKEN ANEMIA VIRUS DNA.
Li et al. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and-independent signaling
DE69636437D1 (en) LIGAND POLYPEPTIDE FOR HYPOPHYSE G PROTEIN COUPLED RECEPTOR PROTEIN, THEIR PREPARATION AND APPLICATION
Wagener et al. The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates interleukin-6 receptor-dependent but retains CNTF receptor-dependent signaling via glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR)
Grunewald et al. A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction
BR9814415A (en) "method for developing, testing and using macromolecule associates and complex aggregates for increased payload and controllable decoupling rates"
SG59954A1 (en) Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
Keegan et al. Regulation of gene expression, growth, and cell survival by IL-4: contribution of multiple signaling pathways

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US

FC4A Lapse of provisional application due to refusal